Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1
- 15 September 2020
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (6), 843-852
- https://doi.org/10.1164/rccm.202001-0105OC
Abstract
Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unknown complication of NF1. Objectives: To describe characteristics and outcomes of PH-NF1. Methods: We reported the clinical, functional, radiologic, histologic, and hemodynamic characteristics, response to pulmonary arterial hypertension (PAH)-approved drugs, and transplant-free survival of patients with PH-NF1 from the French PH registry. Measurements and Main Results: We identified 49 PH-NF1 cases, characterized by a female/male ratio of 3.9 and a median (minimum-maximum) age at diagnosis of 62 (18-82) years. At diagnosis, 92% were in New York Heart Association functional class III or IV. The 6-minute-walk distance was 211 (0-460) m. Pulmonary function tests showed low DLCO (30% [12-79%]) and severe hypoxemia (Pa-O2 56 [38-99] mm Hg). Right heart catheterization showed severe precapillary PH with a mean pulmonary artery pressure of 45 (10) mm Hg and a pulmonary vascular resistance of 10.7 (4.2) Wood units. High-resolution computed tomography images revealed cysts (76%), ground-glass opacities (73%), emphysema (49%), and reticulations (39%). Forty patients received PAH-approved drugs with a significant improvement in functional class and hemodynamic parameters. Transplant-free survival at 1, 3, and 5 years was 87%, 54%, and 42%, respectively, and four patients were transplanted. Pathologic assessment showed nonspecific interstitial pneumonia and major pulmonary vascular remodeling. Conclusions: PH-NF1 is characterized by a female predominance, a low DLCO, and severe functional and hemodynamic impairment. Despite a potential benefit of PAH treatment, prognosis remains poor, and double-lung transplantation is an option for eligible patients.This publication has 38 references indexed in Scilit:
- Pulmonary Hypertension in Patients With Neurofibromatosis Type IMedicine, 2011
- Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial RemodelingCirculation, 2008
- Is Pulmonary Arterial Hypertension in Neurofibromatosis Type 1 Secondary to a Plexogenic Arteriopathy?Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2007
- Neurofibromatosis-associated lung disease: a case series and literature reviewEuropean Respiratory Journal, 2006
- Upstream and downstream of mTORGenes & Development, 2004
- Epidemiology of neurofibromatosis type 1American Journal of Medical Genetics, 1999
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994
- Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patientsNature, 1992
- A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.Journal of Medical Genetics, 1989
- Interstitial Pulmonary Fibrosis and von Recklinghausen’s Disease. An Ultrastructural and Immunofluorescent StudySocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1973